GlassScriptPhysician profile
Pierre Sakali
NPI 1689769663
$24,935.85
in general payments reported to CMS, 2019-2025
35 companies · $2,048 in 2025
The $2,048 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,306 · 2020: $904 · 2021: $5,669 · 2022: $6,749 · 2023: $7,042 · 2024: $1,219 · 2025: $2,048.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,349 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,875 · Education: $62.78 · Consulting Fee: $21.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,348.57 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,875.00 |
| Education | $62.78 |
| Consulting Fee | $21.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $14,734.27 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $2,360.94 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Genzyme Corporation | $1,079.15 | 2019-2025 | |
| Csl Behring | $1,022.58 | 2019-2025 | Hizentra, Haegarda, Privigen |
| Takeda Pharmaceuticals U.S.A., INC. | $939.83 | 2020-2025 | Cuvitru, Hyqvia, Takhzyro |
| Regeneron Healthcare Solutions, INC. | $686.56 | 2019-2025 | Dupixent |
| Pharming Healthcare, INC. | $682.63 | 2019-2025 | Ruconest, Joenja |
| Amgen INC. | $635.07 | 2021-2025 | Tezspire |
| Biocryst US Sales Co., LLC | $409.68 | 2021-2025 | Orladeyo |
| Novartis Pharmaceuticals Corporation | $306.68 | 2019-2025 | |
| Optinose US, INC. | $275.64 | 2019-2022 | |
| Grifols USA, LLC | $254.66 | 2019-2025 | Xembify |
| Genentech USA, INC. | $207.75 | 2019-2025 | Xolair |
| Kaleo, INC. | $179.46 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $170.59 | 2019-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $129.11 | 2019 | |
| Galderma Laboratories, L.P. | $94.90 | 2025 | Nemluvio |
| Pfizer INC. | $88.40 | 2019-2024 | |
| Leo Pharma INC. | $83.89 | 2023-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $70.20 | 2025 | Ebglyss |
| Covis Pharma Gmbh | $68.54 | 2021 | |
| Sanofi-Aventis U.S. LLC | $65.37 | 2021 | |
| Bio Products Laboratory USA, INC. | $57.77 | 2022-2023 | Coagadex, Gammaplex |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.33 | 2020 | |
| Abbott Laboratories | $48.12 | 2023 | Mitraclip |
| Cycle Pharmaceuticals INC | $44.45 | 2025 | Sajazir |
| Adma Biomanufacturing LLC | $35.83 | 2022-2025 | |
| Biocryst Pharmaceuticals, INC. | $34.22 | 2020 | |
| Blueprint Medicines Corporation | $24.69 | 2025 | Ayvakit |
| Sunovion Pharmaceuticals INC. | $18.34 | 2019 | |
| Kedrion Biopharma, INC. | $18.33 | 2024 | Albuked, Rhogam Ultra-Filtered Plus, Kedrab |
| Ionis Pharmaceuticals, INC. | $17.67 | 2025 | Dawnzera |
| Ars Pharmaceuticals Operations, INC. | $14.81 | 2025 | Neffy |
| Viatris Specialty LLC | $13.51 | 2025 | Yupelri |
| Gc Biopharma USA, INC. | $7.88 | 2024 | Alyglo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pierre Sakali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.